First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
NCT06238752
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG:
Apatinib Combined With Tislelizumab and Chemotherapy
Sponsor
Renmin Hospital of Wuhan University